Welcome to our dedicated page for Atai Beckley SEC filings (Ticker: ATAI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The AtaiBeckley Inc. (NASDAQ: ATAI) SEC filings page on Stock Titan provides access to the company’s regulatory documents as filed with the U.S. Securities and Exchange Commission. AtaiBeckley, a clinical-stage biopharmaceutical and biotechnology company focused on mental health treatments, uses SEC reports to disclose material events, financing activities, corporate transactions and updates related to its clinical pipeline.
Investors researching ATAI can review current and historical filings such as Form 8-K reports that describe significant developments. Recent 8-K filings have addressed topics including the completion of the acquisition of Beckley Psytech Limited and the resulting name change to Atai Beckley N.V., public offerings of common shares to fund clinical programs, FDA Breakthrough Therapy designation for BPL-003 in treatment-resistant depression, and the redomiciliation process that led to AtaiBeckley Inc. becoming a Delaware corporation. Other filings detail shareholder votes on the Beckley Psytech transaction and redomiciliation, as well as prospectus supplements related to registered offerings and resales.
Through this page, users can also locate references to AtaiBeckley’s financial reporting, such as earnings press releases furnished on Form 8-K, and legal or transactional documents filed as exhibits, including share purchase agreements and underwriting agreements. These materials help explain how AtaiBeckley finances the development of its key programs BPL-003, VLS-01 and EMP-01 and how it structures its corporate operations.
Stock Titan enhances the ATAI filings page with AI-powered summaries that highlight the main points of lengthy documents, helping readers quickly understand the significance of each filing. Real-time updates from the SEC’s EDGAR system ensure new AtaiBeckley filings appear promptly, while dedicated sections make it easier to find items such as current reports, registration statements and, when available, insider transaction reports on Form 4. This combination of raw filings and AI-generated insights can support deeper due diligence on AtaiBeckley’s regulatory and financial disclosures.
AtaiBeckley Inc. Chief Medical Officer Craig Kevin James executed a pre-planned option exercise-and-sale transaction involving company common stock. On the reported date, he sold 42,579 shares of common stock in an open-market sale at $5.00 per share and exercised stock options covering a total of 42,579 shares at exercise prices of $1.84 and $1.50 per share. The filing states that these option exercises and related sales were carried out under a Rule 10b5-1 trading plan adopted on December 19, 2025, indicating the trades were pre-arranged rather than timed discretionarily.
AtaiBeckley Inc. is asking stockholders to vote at its 2026 virtual annual meeting on June 4, 2026. The proxy seeks approval to elect three Class I directors — Sabrina Martucci Johnson, Amir Kalali, M.D., and Andrea Heslin Smiley — to terms ending at the 2029 annual meeting, and to ratify Deloitte & Touche LLP as independent auditor for 2026.
Holders of 366,916,896 common shares outstanding as of April 9, 2026 are entitled to one vote per share and may vote online, by telephone, or by mail. The company highlights its recent strategic combination of atai Life Sciences and Beckley Psytech and redomiciliation to Delaware, a classified nine‑member board, standard Nasdaq-based independence, and policies covering clawbacks, anti‑hedging, insider trading, and related‑party approvals.
The proxy details security ownership, including a 15.0% stake held by Apeiron Investment Group Ltd., board and committee composition, meeting procedures for the fully virtual format, auditor fees, and prior capital raises in 2025 via a public offering and PIPE financing that included significant Apeiron participation.
Morgan Stanley Smith Barney LLC Executive Financial Services filed a Rule 144 notice to sell 42,579 shares of Common Stock on 04/20/2026, described as resulting from an exercise of stock options and to be settled for cash. The filing lists the transaction as through an issuer-directed exercise.
The excerpt also discloses a prior 10b5-1 sale by Kevin James Craig of 100,000 shares on 03/20/2026 for proceeds of $355,480.00.
AtaiBeckley Inc. director and ten percent owner Christian Angermayer exercised stock options to acquire a total of 559,232 shares of common stock on April 8, 2026. The options were exercised at prices of $1.34, $1.64 and $1.88 per share.
Following these exercises, Angermayer holds 559,232 ATAI shares directly, in addition to substantial indirect holdings, including 1,799,302 shares held by Apeiron Presight Capital Fund II, L.P. and 53,412,414 shares held by Apeiron Investment Group Ltd. The filing shows option exercises only, with no reported open-market sales.
Atai Beckley N.V. (ATAI) reported a change to a director’s stock option. A previously granted option to purchase 40,400 common shares at an exercise price of $4.48 per share was amended on November 25, 2025 in connection with a consulting agreement.
Following the amendment, the reporting person now holds an option covering 10,000 common shares at the same exercise price of $4.48. Instead of vesting in 12 monthly installments beginning December 5, 2025, the option will vest in full on December 31, 2025, if the reporting person continues to provide service through that date.
Atai Beckley N.V. reported Q3 2025 results showing modest revenue but a larger loss driven by fair value changes and operating costs. Total revenue was $749 thousand, primarily from research and development services. Operating expenses reached $29.2 million (R&D $14.7 million, G&A $14.5 million), leading to a loss from operations of $28.4 million. Other expense was weighed by a $32.6 million net change in fair value of assets and liabilities. Net loss was $61.1 million (basic and diluted loss per share $0.28).
Year‑to‑date, revenue totaled $3.023 million and net loss was $115.3 million. Liquidity improved versus year‑end with $30.4 million in cash and cash equivalents, $84.2 million in securities carried at fair value, and $11.4 million in digital assets. Management states existing cash and short‑term securities as of September 30, 2025 will be sufficient to fund operations for at least the next 12 months from issuance. Financing activities included $118.2 million in equity offering proceeds, $21.5 million from pre‑funded warrants, and elimination of long‑term debt.
As of November 10, 2025, shares outstanding were 363,190,522. The company closed its strategic combination with Beckley Psytech on November 5, 2025 and changed its name to Atai Beckley N.V.
Atai Beckley N.V. (ATAI) furnished an update via Form 8-K, noting it issued a press release announcing financial results for the quarter ended September 30, 2025 and provided corporate and clinical updates. The press release is attached as Exhibit 99.1. The company stated the information under Item 2.02, including Exhibit 99.1, is being furnished and is not deemed filed under Section 18 of the Exchange Act or incorporated by reference unless specifically noted.
Atai Beckley N.V. (ATAI) reported insider activity on November 5, 2025. A director received several stock option grants: three fully vested options at an exercise price of $1.35 covering 456,011, 97,716, and 62,394 common shares with expirations from July 2025 to October 2032, and an additional 103,000 options at $4.48 expiring in November 2035 that vest on the first anniversary of the grant date.
On the same date, the company completed its acquisition of Beckley Psytech Limited, issuing 103,000,066 common shares as consideration or as underlying replacement awards pursuant to the purchase agreement.